Free Trial

HLS Therapeutics Q3 2023 Earnings Report

HLS Therapeutics logo
C$3.62 +0.02 (+0.56%)
(As of 12/18/2024 05:28 PM ET)

HLS Therapeutics EPS Results

Actual EPS
-C$0.28
Consensus EPS
-C$0.16
Beat/Miss
Missed by -C$0.12
One Year Ago EPS
N/A

HLS Therapeutics Revenue Results

Actual Revenue
$21.52 million
Expected Revenue
$21.97 million
Beat/Miss
Missed by -$450.00 thousand
YoY Revenue Growth
N/A

HLS Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

AI breakthrough about to upend industry (Ad)

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

HLS Therapeutics Earnings Headlines

HLS Therapeutics (TSE:HLS) Shares Down 0.3% - Here's Why
Optimistic Buy Rating for HLS Therapeutics Despite Revenue Challenges
AI breakthrough about to upend industry
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
See More HLS Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email.

About HLS Therapeutics

HLS Therapeutics (TSE:HLS), a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

View HLS Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings